AC-45613 - oxaliplatin-99 | 61825-94-3

Inorganic or organic compounds of precious metals, whether or not chemically defined, or amalgams of precious metals, nesoi

Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis.

Oxaliplatin

Oxaliplatin

<p>Applications Third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic.<br>References Kidani, Y., et al.: J. Med. Chem., 21, 1315 (1978), Kizu, R., et al.: Cancer Chemother. Pharmacol., 31, 475 (1993), Levi, F., et al.: Eur. J. Cancer, 29A, 1280 (1993), Simpson, D., et al.: Drugs, 63, 2127 (2003),<br></p>

Oxaliplatin is a platinum-based DNA-cross-linking agent. It is a chemotherapeutic drug, often used in combination with leucovorin, fluorouracil, and capecitabine. Oxaliplatin works by cross-linking DNA thus inhibiting the synthesis of RNA and proteins, which leads to cell death and inhibition of cancer cells growth. It is more effective than cisplatin or irinotecan in treating metastatic cancer. Oxaliplatin also has effects on Toll-like receptor 4 (TLR4) expression levels in vitro and in vivo models. In addition, oxaliplatin's effect on ATP binding cassette transporter proteins may be responsible for its antitumour activity against solid tumours.

OXALIPLATIN CRS